SCHEMBL1014912

SCHEMBL1014912

CCN(C(=O)CSCC(=O)Nc1ccc(Cl)cc1C(=O)O)c1cc(-c2ccc(F)cc2)ccc1C

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GAA P10253 2/20 0.39
SERPINE1 P05121 3/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
GRIK1 P39086 1/20 0.37
CASP6 P55212 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014811 0.92 ALDH1A1 (0.45) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1013740 0.88 SERPINE1 (0.51) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1015677 0.87 KDM4E (0.44) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1015814 0.86 LMNA (0.43) KDM4EALDH1A1SMN1; SMN2GAASERPINE1
SCHEMBL1013719 0.80 SERPINE1 (0.44) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1016668 0.79 RXFP1 (0.40) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1013901 0.79 MAPT (0.41) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL17530241 0.78 SERPINE1 (0.52) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1014731 0.77 SERPINE1 (0.41) KDM4EALDH1A1SMN1; SMN2GAASERPINE1
SCHEMBL1019407 0.77 SERPINE1 (0.54) MEN1KMT2AALDH1A1SERPINE1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 MEN1 892/4885KMT2A 3970/4885KDM4E 4108/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 MEN1 1229/4885KMT2A 3323/4885KDM4E 4253/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 MEN1 1187/4885KMT2A 3437/4885KDM4E 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.